Viatris Wins U.S. FDA Approval for Gwyn Lo Contraceptive
PITTSBURGH, July 29, 2026 Viatris Inc. has received U.S. Food and Drug Administration (FDA) approval for Gwyn Lo™ (norelgestromin...
Contraception
Advertisement
Organon Completes Global MIUDELLA® Licensing Agreement
JERSEY CITY, N.J., June 22, 2026 Organon has completed a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA®, a...
FDA Authorizes Signati Medical’s Multi-Center Trial for Separo System
PROVIDENCE, Rhode Island, USA, June 2, 2026 Signati Medical has achieved a significant regulatory milestone after receiving U.S. Food...
Arrowhead REDEMPLO siRNA Drug Approved in Australia
Pasadena, USA | May 1, 2026 Arrowhead Pharmaceuticals has received approval from Australia’s Therapeutic Goods Administration (TGA) for REDEMPLO®...
Viatris Low-Dose Estrogen Patch Phase 3 Data Update
Pittsburgh, USA | May 1, 2026 Viatris has announced multiple clinical data presentations for its investigational low-dose estrogen combined...
Advertisement
